Overview
The company is developing Launch-iT, a novel platform to create virus-targeted immunotherapies that address virus-driven cancers and other diseases. Their approach targets viral infections before they cause cancer, opening a new therapeutic space alongside prevention and treatment. The company focuses on conditions like HPV-driven cancer.
Key people
In the news
- Honored to be featured in Trends' 50 Belgians set to drive impact in the next 50 years. Thank you Benny Debruyne and the team for recognizing the work we're doing in advancing new vaccine approaches with our Launch-iT technology. It reflects not just my work, but the incredible team at Astrivax Therapeutics and our founders at KU Leuven. Let's keep building on our Belgian innovation ecosystem! #immunotherapy #vaccines #HPV #team #4yearsupandrunning #biotech #Belgium #letskeepbuilding Johan Neyts Kai Dallmeier
- We are pleased to share that our CEO Hanne Callewaert and our strategic advisor Gregory Fanning will be attending the 𝗕𝗜𝗢 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗼𝗻𝘃𝗲𝗻𝘁𝗶𝗼𝗻 𝟮𝟬𝟮𝟲 in San Diego. From 𝗝𝘂𝗻𝗲 𝟮𝟮–𝟮𝟱, the global biotech community will come together to exchange insights, build partnerships, and drive innovation across life sciences. We look forward to connecting with partners, collaborators, and investors to explore opportunities on 𝗟𝗮𝘂𝗻𝗰𝗵-𝗶𝗧, 𝗼𝘂𝗿 𝗶𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘁𝗼 𝘁𝗿𝗲𝗮𝘁
Something wrong or missing? Send an update. Fixed within 24 hours.